Business Description
Eton Pharmaceuticals Inc
NAICS : 325412
SIC : 2834
ISIN : US29772L1089
Description
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.32 | |||||
| Equity-to-Asset | 0.5 | |||||
| Debt-to-Equity | 0.32 | |||||
| Debt-to-EBITDA | 3.39 | |||||
| Interest Coverage | 3.27 | |||||
| Piotroski F-Score | 6/9 | |||||
| Altman Z-Score | 0.5 | |||||
| Beneish M-Score | -2.84 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 751.3 | |||||
| 3-Year EBITDA Growth Rate | 79.4 | |||||
| 3-Year EPS without NRI Growth Rate | 68.9 | |||||
| 3-Year Book Growth Rate | -2.2 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 45.63 | |||||
| 9-Day RSI | 50.91 | |||||
| 14-Day RSI | 50.52 | |||||
| 6-1 Month Momentum % | -10.14 | |||||
| 12-1 Month Momentum % | -13.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.59 | |||||
| Quick Ratio | 1.43 | |||||
| Cash Ratio | 1.09 | |||||
| Days Inventory | 34.87 | |||||
| Days Sales Outstanding | 36.4 | |||||
| Days Payable | 58.97 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | 0.92 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 66.24 | |||||
| Operating Margin % | 1.58 | |||||
| Net Margin % | 2.66 | |||||
| FCF Margin % | 11.68 | |||||
| ROE % | 6.02 | |||||
| ROA % | 3.07 | |||||
| ROIC % | 5.33 | |||||
| ROC (Joel Greenblatt) % | 319.58 | |||||
| ROCE % | 3.01 |
GF Value Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 91 | |||||
| Forward PE Ratio | 14.55 | |||||
| PE Ratio without NRI | 91 | |||||
| Price-to-Owner-Earnings | 134.81 | |||||
| PEG Ratio | 1.51 | |||||
| PS Ratio | 2.74 | |||||
| PB Ratio | 6.04 | |||||
| Price-to-Tangible-Book | 10.26 | |||||
| Price-to-Free-Cash-Flow | 23.79 | |||||
| Price-to-Operating-Cash-Flow | 16.11 | |||||
| EV-to-EBIT | 151.07 | |||||
| EV-to-EBITDA | 55.25 | |||||
| EV-to-Revenue | 2.39 | |||||
| EV-to-Forward-Revenue | 1.98 | |||||
| EV-to-FCF | 20.43 | |||||
| Price-to-Graham-Number | 6.41 | |||||
| Price-to-Net-Current-Asset-Value | 10.26 | |||||
| Price-to-Net-Cash | 71.8 | |||||
| Earnings Yield (Greenblatt) % | 0.66 | |||||
| FCF Yield % | 4.29 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:ETON
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Eton Pharmaceuticals Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 34.304 | ||
| EPS (TTM) ($) | 0.04 | ||
| Beta | 0.96 | ||
| Volatility % | 76.38 | ||
| 14-Day RSI | 50.52 | ||
| 14-Day ATR ($) | 0.197325 | ||
| 20-Day SMA ($) | 3.56625 | ||
| 12-1 Month Momentum % | -13.08 | ||
| 52-Week Range ($) | 2.42 - 5.81 | ||
| Shares Outstanding (Mil) | 25.69 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 6 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Eton Pharmaceuticals Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Eton Pharmaceuticals Inc Stock Events
| Event | Date | Price($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Eton Pharmaceuticals Inc Frequently Asked Questions
What is Eton Pharmaceuticals Inc(ETON)'s stock price today?
The current price of ETON is $3.59. The 52 week high of ETON is $5.81 and 52 week low is $2.42.
When is next earnings date of Eton Pharmaceuticals Inc(ETON)?
The next earnings date of Eton Pharmaceuticals Inc(ETON) is 2024-08-09 Est..
Does Eton Pharmaceuticals Inc(ETON) pay dividends? If so, how much?
Eton Pharmaceuticals Inc(ETON) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers